Romidepsin (FK228, Depsipeptide)

Catalog No.S3020

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Romidepsin (FK228, Depsipeptide) Chemical Structure

Romidepsin (FK228, Depsipeptide) Chemical Structure
Molecular Weight: 540.7

Validation & Quality Control

3 customer reviews :

Quality Control & MSDS

Related Compound Libraries

Romidepsin (FK228, Depsipeptide) is available in the following compound libraries:

HDAC Inhibitors with Unique Features

Product Information

  • Compare HDAC Inhibitors
    Compare HDAC Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Targets HDAC1 [1]
(Cell-free assay)
HDAC2 [1]
(Cell-free assay)
IC50 36 nM 47 nM
In vitro Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
SU-DHL4NULFfHZkS2WubDDWbYFjcWyrdImgRZN{[Xl?NUjsO4g{Oi53LUG1JI5OMU[3NkBpMkTJbY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>?M2C0SVI2PzlyOUC3
U2932 NGnv[nJE\WyuIG\pZYJqdGm2eTDBd5NigQ>?NIe3S24zNjVvMUWgcm0>NYnuV2ttPzJiaB?=MWPpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKhMmniNlU4QTB7MEe=
OCI-LY7NUTwbZlYS2WubDDWbYFjcWyrdImgRZN{[Xl?MViyMlUuOTVibl2=M4i3TFczKGh?M2jzWYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?MWGyOVc6ODlyNx?=
FarageNHrOR|dE\WyuIG\pZYJqdGm2eTDBd5NigQ>?M1frU|IvPS1zNTDuUS=>M2e0TVczKGh?M3;xVYlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB?Mn;DNlU4QTB7MEe=
LY7/EBVMWTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>NVLTbFBxOi53LUG1JI5OMm\QO|IhcA>?NH\MWWpqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLiMoK3NlU4QTB7MEe=
U2932/EBVMlr5R4VtdCCYaXHibYxqfHliQYPzZZk>MWeyMlUuOTVibl2=Mmi3O|IhcA>?NVnFU4RqcW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?=NIrnc40zPTd7MEmwOy=>
HCT116M4Hu[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUK1MVUxODBibl2=NHr0d48zPCCqNH7OPIRFVVORMkHXbY5lfWOnczDj[YxtKGSnYYToJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyMW[yOVQ6OjVzNR?=
ACH-2NVLlN|NpTnWwY4Tpc44hSXO|YYm=M4LKV|EuQSCwTR?=M3Kwd|I1KGh?NImxN4FqdmS3Y3XzJGhKXi1zIFXuekBmgHC{ZYPzbY9vNFXtNIwzPTF2OUS2Oy=>
MCF-10AM372Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWXJR|UxRTBwMUhCtVAvODFibl2=NF7GbmYzPDl3NEi1Oi=>
MCF-7NUOydpNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXvsW|VNUUN3ME2xMlExyrFyLkKwJI5OMVWyOFk2PDh3Nh?=
SK-BR-3M36zTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnt[nRGUUN3ME2xMlAxyrFyLkO1JI5OM{jhbVI1QTV2OEW2
MDA-MB-231M2Lp[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXXJR|UxRTBwNklCtVAvOTRibl2=M2jUSFI1QTV2OEW2
PC3M4f2WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnnSTWM2OD1zLk[1xtExNjN3IH7NMXGyOFk2PDh3Nh?=
HCT116NXnZTXp[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkTHTWM2OD1zLkCwxtExNjByIH7NM1rvV|I1QTV2OEW2
HCT116-p21-/-NG\oZ|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTHTWM2OD1zLkK2xtExNjN5IH7NNYj6cXpyOjR7NUS4OVY>
S1M2rBW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFLVdppKSzVyPUeuOlfDuTBwMkmgcm0>Mm\0NlQ6PTR6NU[=
SW620NXrNSnR2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTBwOURCtVAvOjlibl2=M3rhWFI1QTV2OEW2
LOX-IMVIMXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MU\JR|UxRTBwOEhCtVAvODNibl2=MXmyOFk2PDh3Nh?=
UACC-62NGHXcZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2W4N2lEPTB;MD61OuKyOC5zNjDuUS=>MlHINlQ6PTR6NU[=
MDA-MB-435MnTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoXMTWM2OD1yLkmwxtExNjB4IH7NMmDuNlQ6PTR6NU[=
SF-295MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkCyTWM2OD1yLki4xtExNjF3IH7NNW[0OoRPOjR7NUS4OVY>
A549NGfaOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX;oelN3UUN3ME2xMlI3yrFyLkK0JI5OM{Tud|I1QTV2OEW2
H460Mmr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MWLJR|UxRTJwNUlCtVAvQDBibl2=NUD4TXlsOjR7NUS4OVY>
EKVXMmDSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkPWTWM2OD1zLkOzxtExNjN2IH7NMlXMNlQ6PTR6NU[=
H146MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4ntO2lEPTB;MD6yNuKyOC5yNzDuUS=>NU[3[WJEOjR7NUS4OVY>
H526M1nlXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MXfJR|UxRTBwMUZCtVAvODNibl2=NFzwSokzPDl3NEi1Oi=>
HuT-78MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnGyTWM2OD1zLkezxtExNjR2IH7NMVWyOFk2PDh3Nh?=
HANGX3boZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXXpNIFIOC54MkWtNVBvVQ>?NHzyVVI1QCCqNUXOXFh2cW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ?NYrE[FlTOjR5N{G1NVA>
MS-275MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWKwMlYzPS1zMH7NMlzrOFghcA>?M4XnV4lv\HWlZYOgZUB{cWewaX\pZ4FvfGy7IIP0do9v\2W{IHnubIljcXSrb36gc4Yh[2WubDDwdo9tcW[ncnH0bY9vKGOxLYTy[YF1\WRid3n0bEBjd3K2ZYrvcYljMX2yOFc4OTVzMB?=
CD4 TMVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXe0PEBpMonRSWM2OD12LkZCtVEvOCCwTR?=M{PPTFI1PzJ{NEW0
CD4 TMl;sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1HNSFQ5KGh?NIXEUYVESzVyPUGwO:KyOTJ4IH7NNUH0WHg6OjR5MkK0OVQ>
CD4+ TNY\lTZhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NIXmcWFGSzVyPUOgcm0>NIO1TpczPDR7NUGwOS=>
A549M2TpVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoTjNVDjiJNzMEFCpI5OMnfTNlQwOzZxNEigbC=>M1\jXIlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIgh[2:wY3XueJJifGmxbj2gZY5lKHSrbXWt[IVx\W6mZX70JI1idm6nch?=M1PufFI1PDh3N{m5
JJN3NIn3ZW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXGwc2J[OjRxNEigbC=>M2TTPGVEPTB:MfMAjY5OQyB2OPMAjYg>MVqyOFA{ODF3MB?=
OPM-2NIXjcVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUmyOE81QCCqM322SWVEPTC|PUJihKlvVTtiNElihKlpMUWyOFA{ODF3MB?=
RPMI-8226MnPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXuyOE81QCCqM3OyN2VEPTC|PUGuPQKBkW6POzC0PQKBkWh?NHjXflMzPDB|MEG1NC=>
U266NETVR3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWWyOE81QCCqMYDFR|Uxez1zMPMAjY5OQyB2OPMAjYg>NFu4WI8zPDB|MEG1NC=>
CA46M2DEUmFxd3C2b4Ppd{BCe3OjeR?=M3;OdFYhcA>?NWrJZWtCcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO=NXW4RoRxOjN7Nk[xOlQ>
DG75MkPiRZBweHSxc3nzJGF{e2G7NUPqW5NIPiCqNFzrSpdqdmS3Y3XzJI5wKGGyb4D0c5Nqew>?M3PiSlI{QTZ4MU[0
RamosMmHIRZBweHSxc3nzJGF{e2G7MnS2OkBpMVHpcoR2[2W|IHX4eIVve2m4ZTDhdI9xfG:|aYO=MlzUNlM6PjZzNkS=
ST486NELlUXVCeG:ydH;zbZMhSXO|YYm=M4LaR|YhcA>?MnrGbY5lfWOnczDlfJRmdnOrdnWgZZBweHSxc3nzNG\nUlEzOzl4NkG2OC=>
HuT78MXjBdI9xfG:|aYOgRZN{[Xl?NVK3c25tOS9zMD:xNFAhdk1?NGHWdmU1QCCqNUe3RYl6cW6mdXPld{BieG:ydH;zbZMh[XRiMTDuUS=>MVeyN|U{Ojd|Mh?=
DpVp35MWLBdI9xfG:|aYOgRZN{[Xl?NFnaZXcyNzFyL{GwNEBvVQ>?M3fSSVQ5KGh?NFHWfZFqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?=NHHn[GEzOzV|MkezNi=>
DpVp50NXzh[FNnSXCxcITvd4l{KEG|c3H5M{fBd|EwOTBxMUCwJI5OMofSOFghcA>?NVXGW|FTcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO=NUm4UIlwOjN3M{K3N|I>
DpP75 MkCzRZBweHSxc3nzJGF{e2G7NX:3O5lkOS9zMD:xNFAhdk1?NGrMOmk1QCCqMY\pcoR2[2W|IHLseY51KGGyb4D0c5Nqew>?MnHMNlM2OzJ5M{K=
SKOV-3MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MUex5qCUOjCwTR?=NUjF[YVZPzJiaB?=M2OwbmROW09?NEjP[Jlz\WS3Y3XzJINmdGxidnnhZoltcXS7IHHsc45mKGGwZDDjc41jcW6nZDD3bZRpKGOrc4DsZZRqdg>?NX36[3dFOjNyMUCzOFg>
Brca1 WTMoPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGKxeGIy6oDVMkDuUS=>NXK0clBnPzJiaB?=M2TScWROW09?NVXLXnlSemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5?NELlZ4gzOzBzMEO0PC=>
Brca1 NullMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYDIe3hiOeLCk{Kwcm0>MYq3NkBpMn3LSG1UVw>?NX:3OGsyemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5?M{nH[|I{ODFyM{S4
OVCAR-8 MoXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{H6c|HjiJN{MH7NMYm3NkBpNFLzeINFVVORMmLxdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4>NVLpdIJvOjNyMUCzOFg>
NCI/ADR-RESMnv3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NE\O[Vcy6oDVMkDuUS=>NH65O2U4OiCqNVzDOW41TE2VTx?=MnP0doVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4>M33uTVI{ODFyM{S4
HCT116M4\5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmL0OUBvVS13MDFOwG0>MXGyOEBpNH3tVWZFVVORNUjmdGJ7cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ?NXG5OGlnOjJ7MkS5OVg>
RKOM17PN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NW\scm13PSCwTT21NEDPxE1?M2rCR|I1KGh?MkHPSG1UVw>?MVnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=>MXqyNlkzPDl3OB?=
CO115MoPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXjjdIdCPSCwTT21NEDPxE1?MVyyOEBpM{XqSGROW09?MoH6bY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI>MUGyNlkzPDl3OB?=
HFSM2rNWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV3HWHhzPSCwTR?=NXqzT|VzOjRxNEivO|IhcA>?M{PsTIlvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk>NGPsXWozOjFyNkK4Ni=>
LNCaPM1POXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MoPwOUBvVQ>?NUK2fIZ{OjRxNEivO|IhcA>?M1TZW4lvcGmkaYTzJINmdGxiZ4Lve5RpKHSrbXWt[IVx\W6mZX70cJk>MlvUNlIyODZ{OEK=
A549M4PGSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmnTOUBvVQ>?M{fYbVI1NzR6L{eyJIg>NUThPG44cW6qaXLpeJMh[2WubDDndo94fGhidHnt[U1l\XCnbnTlcpRtgQ>?M3fDU|IzOTB4Mkiy
697 M3n6[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml;tTWM2OOLCiU5ihKkzNjYEoH7NMn;zNlE2Ozh{MU[=
697-RMlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NG\STo9KSzVy4pEJQgKBkThwNtMgcm3DqA>?NUDlSoJ{OjF3M{iyNVY>
HUT78MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYXIUJBrUUN3ME2xJI5ONXi4bWM{OjFzOUi1OFU>
THJ-16TM{nUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVGxJI5OM2\R[|I1KGh?M2XMVIlvcGmkaYTzJINmdGxiZ4Lve5RpNXfV[2FKOjB6MUC1Olg>
HCT116MnuwSpVv[3Srb36gRZN{[Xl?Mlm1NlAhdk1?NGC1Tmw5KGh?NYj3PJN[dW:mdXzheIV{KHS{YX7zZ5JqeHRibHX2[Yx{KG[xcjDoeY5lemWmczDv[kBo\W6nczDpckBmcXSqZYKg[Ilz\WO2aX;uM4[zPVIxPzN7NEW0
B104 M1XuNmZ2dmO2aX;uJGF{e2G7NHrUWFAzKG6PNVPCRZJ7OjRxNEivO|IhcA>?Mke3bY5kemWjc3XzJJRp\SC|dYLmZYNmKGW6cILld5Nqd25ib3[gR2QzOMLiNHH2bm4zODZ6NkWwOS=>
HL-60 M37nZmN6fG:2b4jpZ4l1gSCDc4PhfS=>NGrtO2UyNTVyMDDuUS=>NGHYNWczPCCqNELNOoxqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLiMUKyNFYzPDF4Mx?=
HP100M4TmS2N6fG:2b4jpZ4l1gSCDc4PhfS=>MYmxMVUxOCCwTR?=MWKyOEBpNGTPVGdqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLiNHz2ZoEzODZ{NEG2Ny=>
HL-60 Ml3HSpVv[3Srb36gRZN{[Xl?MU[xNEBvVQ>?NU\ubVB3PC94L{G2JIg>MXTpcoR2[2W|IITo[UBo\W6ncnH0bY9vKG:oIHj5[JJw\2WwIIDldo95cWSnIH\yc40hPGh?MVmyNFYzPDF4Mx?=
HP100M1vtcGZ2dmO2aX;uJGF{e2G7MoLQNVAhdk1?NEK3WYE1NzZxMU[gbC=>NEXIXY1qdmS3Y3XzJJRp\SCpZX7ldoF1cW:wIH;mJIh6\HKxZ3XuJJBmem:6aXTlJIZzd21iNHi=NXXBPJY3OjB4MkSxOlM>
HL-60 NHnnXpFHfW6ldHnvckBCe3OjeR?=MVSxNE02ODBibl2=M2C0XFQhcA>?MYfk[YNz\WG|ZYOgeIhmKGirc4TvcoUh\GWjY3X0fYxie2ViKFjERWMqKGGldHn2bZR6yqB?MmC5NlA3OjRzNkO=
HP100NFXwVopHfW6ldHnvckBCe3OjeR?=MkTNNVAuPTByIH7NMnW5OEBpNV2yZ4hD\GWlcnXhd4V{KHSqZTDobZN1d26nIHTlZYNmfHmuYYPlJEhJTEGFKTDhZ5Rqfmm2edMgMnrNNlA3OjRzNkO=
11zMWnLbY5ie2ViQYPzZZk>Ml3BN{0yODBibl2=NGWzUpNz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?=NWfGPZpsOjB4MEWxOFQ>
SKOV-3M3XXfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NG\Cbnc1NzhxMU[gcm0>NHnMTmQ1QCCqNEHPXWFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?MnjJNlA1ODR3NkS=
OVCAR-3MojXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvKTFQ1NzhxMU[gcm0>M1jFWFQ5KGh?NEK0c|VqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>?MUeyNFQxPDV4NB?=
HBL-2MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGfNcpAzNTFyIH7NNV7sVoFIOjRiaB?=MmnoTWM2OD12LkOgcm0>Mk[3NlAxPjhyOEC=
Jeko-1M1ny[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGfUfJEzNTVyIH7NM4C1SVI1KGh?MX3JR|UxRTFzIH7NMmfiNlAxPjhyOEC=
Granta-519NFGyOHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NU\zUnlvPS12MDDuUS=>MX2yOEBpMmLtTWM2OD13OD61JI5OM4[yUVIxODZ6MEiw
L1236NGXyVpNEgXSxdH;4bYNqfHliQYPzZZk>NF7wOnQyKG6PLUGwNEDPxE1?MnvFOFghcA>?M3zmUmVEPTB;MD6wO{DPxE1?MXixPVI{OzR5MB?=
L428NUPhRYw6S3m2b4TvfIlkcXS7IFHzd4F6NIG5SosyKG6PLUGwNEDPxE1?NGHPc3c1QCCqM{GxNWVEPTB;MD60N{DPxE1?NIX4NZgyQTJ|M{S3NC=>
KM-H2MYTDfZRwfG:6aXPpeJkhSXO|YYm=MUOxJI5ONTFyMDFOwG0>M2TVdVQ5KGh?NUTJbFNiTUN3ME2wMlU5KM7:TR?=Ml7zNVkzOzN2N{C=
L540CyNILDWppEgXSxdH;4bYNqfHliQYPzZZk>MVuxJI5ONTFyMDFOwG0>Ml3nOFghcA>?NIL0U4JGSzVyPUCuNVYh|ryPNFfHNYUyQTJ|M{S3NC=>
G401NV74[lZYTnWwY4Tpc44hSXO|YYm=MmX3NVAhdk1?MlT2NlQwPDhxN{KgbC=>MlSxSG1UVw>?MkH1bY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;uNVrVfWZqOTl{MkG1PFY>
STM91-01MYrGeY5kfGmxbjDBd5NigQ>?M2P2d|ExKG6PNUD6SpZ[OjRxNEivO|IhcA>?NVnpOGx5TE2VTx?=NH3wb2pqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44>Ml\YNVkzOjF3OE[=
SJSC M{iyVWZ2dmO2aX;uJGF{e2G7M3n1SlExKG6PNX3NcZV[OjRxNEivO|IhcA>?NUHFZoJ{TE2VTx?=NIHEfm1qdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44>NIHyV2gyQTJ{MUW4Oi=>
BT16 MWTGeY5kfGmxbjDBd5NigQ>?NULZXGxuOTBibl2=MWWyOE81QC95MjDoMofSSG1UVw>?MmTBbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;uNF[1WWUyQTJ{MUW4Oi=>
NCI-H1299MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnnPTWM2OD12LkdCtVAvOiCwZz;tcC=>MnvRNVkyPzl6OUC=
NCI-2882MmXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFzRZlRKSzVyPUGuOuKyOC5yNDDu[{9udA>?NHK1UIkyQTF5OUi5NC=>
HCC95M1mycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Ml3mTWM2OD1{LkZCtVAvODVibnevcYw>M4[zRVE6OTd7OEmw
NCI-H23NHnyPGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXjJR|UxRTJwOdMxNE4zKG6pL33sMUixPVE4QTh7MB?=
NCI-H157NEPBcItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1XRUGlEPTB;MT62xtExNjB{IH7nM41tMXyxPVE4QTh7MB?=
NCI-H460NGGyRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTJwMdMxNE4xPyCwZz;tcC=>M3j1[VE6OTd7OEmw
NCI-H1975M3jJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7Ie3k6UUN3ME2xMlPDuTBwMESgcocwdWx?NU\kNFJvOTlzN{m4PVA>
NCI-H820MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXnJR|UxRTJwNNMxNE4yKG6pL33sMn;mNVkyPzl6OUC=
NCI-H1650NW\PNFRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnvvTWM2OD12LkpCtVAvOyCwZz;tcC=>NHnrfpkyQTF5OUi5NC=>
DTC1MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MUTJR|UxRTBwNUGgcm0>NEjaVHkyQDV4NkK0Oi=>
KAOMlnhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2\YbmlEPTB;MD65NUBvVQ>?MlrENVg2PjZ{NE[=
SU-CCS-1M1m4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWHWSJh7UUN3ME2wMlg6KG6PMWSxPFU3PjJ2Nh?=
SYO-1NUTVemR1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEW1UWFKSzVyPUCuOlchdk1?NHLpd2QyQDV4NkK0Oi=>
FUJIMkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUG4emNkUUN3ME2xMlMyKG6PMY[xPFU3PjJ2Nh?=
SKNMCMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLkTWM2OD1zLkG3JI5OMkLXNVg2PjZ{NE[=
402-91NEW0ZYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTFwMk[gcm0>NFfwfZkyQDV4NkK0Oi=>
1765-92MnywS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{fDe2lEPTB;MT63O{BvVQ>?NV:xTldPOTh3Nk[yOFY>
JN-DSRCT-1NUS1UY9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkT3TWM2OD1zLkK1JI5OMYmxPFU3PjJ2Nh?=
NMS-2PCNEH2fGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1\6emlEPTB;MD64NUBvVQ>?MXyxPFU3PjJ2Nh?=
HL60MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1TQT2lEPTB;MT64OkBvVQ>?NVq2VpJTOTh3Nk[yOFY>
A549MmG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY\uR3RQUUN3ME2zMlI1KG6PNXXIeZRWOTh3Nk[yOFY>
SW480MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NILUPXFKSzVyPUKuOlkhdk1?MWKxPFU3PjJ2Nh?=
MCF7M3P1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX;YUJVQUUN3ME2zMlU2KG6PM3PaWlE5PTZ4MkS2
PC-3NHi3fm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1vCbGlEPTB;Mj61NUBvVQ>?M3nD[FE5PTZ4MkS2
MMRUNVrZXllQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NF\wU29KSzVyPUKuOVchdk1?NF\yS3EyQDV4NkK0Oi=>
Hs68MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVnzN45DUUN3ME2+NVAhdk1?Mny3NVg2PjZ{NE[=
hMSC-001FM3;UZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mlr5TWM2OD1-MUCgcm0>MlnONVg2PjZ{NE[=

... Click to View More Cell Line Experimental Data

In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.

Protocol(Only for Reference)

Kinase Assay:

[1]

HDAC-inhibitory activity For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.

Cell Assay:

[3]

Cell lines HL60, Jurkat, A549, and MCF-7
Concentrations Dissolved in DMSO, final concentrations ~10 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.

Animal Study:

[5]

Animal Models Male scid mice inoculated i.p. with U-937 cells
Formulation Dissolved in DMSO, and diluted in saline
Dosages ~1 mg/kg once or twice a week
Administration Treated i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Furumai R, et al. Cancer Res, 2002, 62(17), 4916-4921.

[2] Sandor V, et al. Br J Cancer, 2000, 83(6), 817-825.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02850016 Not yet recruiting Human Immunodeficiency Virus (HIV) Rockefeller University|University Hospital of Cologne|Aar  ...more Rockefeller University|University Hospital of Cologne|Aarhus University Hospital August 2016 Phase 2
NCT02757248 Not yet recruiting PTCL|CTCL Anne Beaven, MD|National Comprehensive Cancer Network|Boe  ...more Anne Beaven, MD|National Comprehensive Cancer Network|Boehringer Ingelheim|Duke University July 2016 Phase 1
NCT02281279 Not yet recruiting B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal  ...more B-cell Adult Acute Lymphoblastic Leukemia|Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue|Intraocular Lymphoma|Nodal Marginal Zone B-cell Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent Adult Burkitt Lymphoma|Recurrent Adult Diffuse Large Cell Lymphoma|Recurrent Adult Diffuse Mixed Cell Lymphoma|Recurrent Adult Diffuse Small Cleaved Cell Lymphoma|Recurrent Adult Grade III Lymphomatoid Granulomatosis|Recurrent Adult Immunoblastic Large Cell Lymphoma|Recurrent Adult Lymphoblastic Lymphoma|Recurrent Grade 1 Follicular Lymphoma|Recurrent Grade 2 Follicular Lymphoma|Recurrent Grade 3 Follicular Lymphoma|Recurrent Mantle Cell Lymphoma|Recurrent Marginal Zone Lymphoma|Recurrent Small Lymphocytic Lymphoma|Refractory Hairy Cell Leukemia|Small Intestine Lymphoma|Splenic Marginal Zone Lymphoma|Testicular Lymphoma|Waldenström Macroglobulinemia Mayo Clinic|National Cancer Institute (NCI) June 2016 Phase 1|Phase 2
NCT02783625 Recruiting Lymphoma|Relapsed/Refractory T-cell Lymphomas Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer  ...more Memorial Sloan Kettering Cancer Center|Dana-Farber Cancer Institute|Stanford University May 2016 Phase 1
NCT02616874 Recruiting HIV IrsiCaixa|Germans Trias i Pujol Hospital|Fundacio Lluita  ...more IrsiCaixa|Germans Trias i Pujol Hospital|Fundacio Lluita Contra la SIDA|Hospital Clinic of Barcelona|Hospital de Sant Pau|HIVACAT|University of Oxford|BCN-Checkpoint February 2016 Phase 1

view more

Chemical Information

Download Romidepsin (FK228, Depsipeptide) SDF
Molecular Weight (MW) 540.7
Formula

C24H36N4O6S2

CAS No. 128517-07-7
Storage 3 years -20℃powder
2 years -80℃in solvent
Synonyms FR 901228, NSC 630176
Solubility (25°C) * In vitro DMSO 10 mg/mL (18.49 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 1% DMSO+30% polyethylene glycol+1% Tween 80 18 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl], cyclic (3→5)-disulfide

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related HDAC Products

  • LMK-235

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • 4SC-202

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

  • Entinostat (MS-275)

    Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

  • Tubastatin A

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Recently Viewed Items

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) ic50 | Romidepsin (FK228, Depsipeptide) price | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) solubility dmso | Romidepsin (FK228, Depsipeptide) purchase | Romidepsin (FK228, Depsipeptide) manufacturer | Romidepsin (FK228, Depsipeptide) research buy | Romidepsin (FK228, Depsipeptide) order | Romidepsin (FK228, Depsipeptide) mouse | Romidepsin (FK228, Depsipeptide) chemical structure | Romidepsin (FK228, Depsipeptide) mw | Romidepsin (FK228, Depsipeptide) molecular weight | Romidepsin (FK228, Depsipeptide) datasheet | Romidepsin (FK228, Depsipeptide) supplier | Romidepsin (FK228, Depsipeptide) in vitro | Romidepsin (FK228, Depsipeptide) cell line | Romidepsin (FK228, Depsipeptide) concentration | Romidepsin (FK228, Depsipeptide) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us